SEC approves Covaxin Phase 3 trials efficacy data
A Bharat Biotech official said the company is in talks with at least four companies for the transfer of technology (ToT) to produce COVID-19 vaccine Covaxin, but only one of them can start manufacturing soon.
Only Indian Immunologicals is likely to start manufacturing soon since the others do not have the manufacturing facilities in place yet.
"Technology transfer to Indian Immunologicals is underway, and we expect that they will start manufacturing the vaccine very soon. The government of India has introduced three other companies to us for the transfer of technology, and we are in discussions with them as well. But these are a little behind the curve, as none of them have manufacturing facilities yet," the official told the publication.
On April 20, Bharat Biotech had said it plans to scale manufacturing capacity to 700 million doses of Covaxin annually.
The company is actively working on obtaining a biologics licence application (BLA) for Covaxin to make the jab available in the US it said. The US Food and Drug Administration (USFDA) recently turned down an application to grant emergency use authorisation (EUA) to Covaxin.